Angiotensin II receptor blockade during gestation attenuates collagen formation in the developing rat heart

Steffen Lamparter, Yao Sun, Karl Weber

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: Fetal cardiac development includes rapid formation of a three-dimensional collagen network, composed mainly of type I and III fibrillar collagens. Collagen fibrils have been found in cardiac jelly at very early stages of cardiac development and are thought to have structural and functional properties. In adult rat cardiac tissue, angiotensin II (AngII) via AT1 receptor binding and AngII-regulated expression of transforming growth factor beta-1 (TGF-β1) each upregulate collagen transcription. AT1 and AT2 receptor subtypes are developmentally regulated; both have been localized in fetal tissue where the AT2 receptor is considered a determinant of morphogenesis. We sought to determine whether blockade of either receptor would result in attenuation of collagen mRNA expression and fibrillar collagen accumulation and alter TGF-β1 mRNA expression in the developing fetal heart examined at birth. Methods: Pregnant rats were treated either with an AT1 receptor antagonist losartan or an AT2 receptor antagonist PD123319 and compared with untreated age-matched controls. Offspring were studied within 24 h of birth. Type I and type III collagen mRNA expression, as well as TGF-β1 mRNA expression, were examined by in situ hybridization. Collagen concentration was determined spectrophotometrically by picrosirius red staining and type I and III collagens were detected by immunoblotting. Results: We found: (1) comparable birth weights in control and PD123319- treated animals, but reduced body weight in newborn losartan-treated animals; (2) compared to untreated animals, type I collagen and TGF-β1 mRNA expression in cardiac tissue were each equally reduced in both losartan and PD123319-treated animals; (3) increased type III collagen mRNA expression in both PD123319- and losartan-treated groups; and (4) a significant decrease in total soluble cardiac collagen concentration in both losartan and PD123319- treated groups, confirmed by attenuated immunoreactivity of type I and III collagens in whole heart extracts by Western blotting. Conclusions: The results of these pharmacologic interventions suggest AngII receptors are expressed in cardiac tissue during gestation, where both AT1 and AT2 receptors are involved in the regulation of type I and III collagen expression and structural protein accumulation. These effects appear to be mediated, in part, by attenuated cardiac TGFβ1 levels. The marked decrease in newborn cardiac collagen content has yet undefined functional consequences.

Original languageEnglish (US)
Pages (from-to)165-172
Number of pages8
JournalCardiovascular research
Volume43
Issue number1
DOIs
StatePublished - Jan 1 1999

Fingerprint

Angiotensin Receptors
Collagen Type III
Losartan
Collagen
Pregnancy
Collagen Type I
Messenger RNA
Transforming Growth Factor beta
Fibrillar Collagens
Parturition
Transforming Growth Factor beta1
Fetal Heart
Angiotensin Type 1 Receptor
Fetal Development
Morphogenesis
Immunoblotting
Birth Weight
Angiotensin II
In Situ Hybridization
Fetus

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Angiotensin II receptor blockade during gestation attenuates collagen formation in the developing rat heart. / Lamparter, Steffen; Sun, Yao; Weber, Karl.

In: Cardiovascular research, Vol. 43, No. 1, 01.01.1999, p. 165-172.

Research output: Contribution to journalArticle

@article{420e769308004b00bad6a89a6c6487e7,
title = "Angiotensin II receptor blockade during gestation attenuates collagen formation in the developing rat heart",
abstract = "Objective: Fetal cardiac development includes rapid formation of a three-dimensional collagen network, composed mainly of type I and III fibrillar collagens. Collagen fibrils have been found in cardiac jelly at very early stages of cardiac development and are thought to have structural and functional properties. In adult rat cardiac tissue, angiotensin II (AngII) via AT1 receptor binding and AngII-regulated expression of transforming growth factor beta-1 (TGF-β1) each upregulate collagen transcription. AT1 and AT2 receptor subtypes are developmentally regulated; both have been localized in fetal tissue where the AT2 receptor is considered a determinant of morphogenesis. We sought to determine whether blockade of either receptor would result in attenuation of collagen mRNA expression and fibrillar collagen accumulation and alter TGF-β1 mRNA expression in the developing fetal heart examined at birth. Methods: Pregnant rats were treated either with an AT1 receptor antagonist losartan or an AT2 receptor antagonist PD123319 and compared with untreated age-matched controls. Offspring were studied within 24 h of birth. Type I and type III collagen mRNA expression, as well as TGF-β1 mRNA expression, were examined by in situ hybridization. Collagen concentration was determined spectrophotometrically by picrosirius red staining and type I and III collagens were detected by immunoblotting. Results: We found: (1) comparable birth weights in control and PD123319- treated animals, but reduced body weight in newborn losartan-treated animals; (2) compared to untreated animals, type I collagen and TGF-β1 mRNA expression in cardiac tissue were each equally reduced in both losartan and PD123319-treated animals; (3) increased type III collagen mRNA expression in both PD123319- and losartan-treated groups; and (4) a significant decrease in total soluble cardiac collagen concentration in both losartan and PD123319- treated groups, confirmed by attenuated immunoreactivity of type I and III collagens in whole heart extracts by Western blotting. Conclusions: The results of these pharmacologic interventions suggest AngII receptors are expressed in cardiac tissue during gestation, where both AT1 and AT2 receptors are involved in the regulation of type I and III collagen expression and structural protein accumulation. These effects appear to be mediated, in part, by attenuated cardiac TGFβ1 levels. The marked decrease in newborn cardiac collagen content has yet undefined functional consequences.",
author = "Steffen Lamparter and Yao Sun and Karl Weber",
year = "1999",
month = "1",
day = "1",
doi = "10.1016/S0008-6363(99)00111-X",
language = "English (US)",
volume = "43",
pages = "165--172",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Angiotensin II receptor blockade during gestation attenuates collagen formation in the developing rat heart

AU - Lamparter, Steffen

AU - Sun, Yao

AU - Weber, Karl

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Objective: Fetal cardiac development includes rapid formation of a three-dimensional collagen network, composed mainly of type I and III fibrillar collagens. Collagen fibrils have been found in cardiac jelly at very early stages of cardiac development and are thought to have structural and functional properties. In adult rat cardiac tissue, angiotensin II (AngII) via AT1 receptor binding and AngII-regulated expression of transforming growth factor beta-1 (TGF-β1) each upregulate collagen transcription. AT1 and AT2 receptor subtypes are developmentally regulated; both have been localized in fetal tissue where the AT2 receptor is considered a determinant of morphogenesis. We sought to determine whether blockade of either receptor would result in attenuation of collagen mRNA expression and fibrillar collagen accumulation and alter TGF-β1 mRNA expression in the developing fetal heart examined at birth. Methods: Pregnant rats were treated either with an AT1 receptor antagonist losartan or an AT2 receptor antagonist PD123319 and compared with untreated age-matched controls. Offspring were studied within 24 h of birth. Type I and type III collagen mRNA expression, as well as TGF-β1 mRNA expression, were examined by in situ hybridization. Collagen concentration was determined spectrophotometrically by picrosirius red staining and type I and III collagens were detected by immunoblotting. Results: We found: (1) comparable birth weights in control and PD123319- treated animals, but reduced body weight in newborn losartan-treated animals; (2) compared to untreated animals, type I collagen and TGF-β1 mRNA expression in cardiac tissue were each equally reduced in both losartan and PD123319-treated animals; (3) increased type III collagen mRNA expression in both PD123319- and losartan-treated groups; and (4) a significant decrease in total soluble cardiac collagen concentration in both losartan and PD123319- treated groups, confirmed by attenuated immunoreactivity of type I and III collagens in whole heart extracts by Western blotting. Conclusions: The results of these pharmacologic interventions suggest AngII receptors are expressed in cardiac tissue during gestation, where both AT1 and AT2 receptors are involved in the regulation of type I and III collagen expression and structural protein accumulation. These effects appear to be mediated, in part, by attenuated cardiac TGFβ1 levels. The marked decrease in newborn cardiac collagen content has yet undefined functional consequences.

AB - Objective: Fetal cardiac development includes rapid formation of a three-dimensional collagen network, composed mainly of type I and III fibrillar collagens. Collagen fibrils have been found in cardiac jelly at very early stages of cardiac development and are thought to have structural and functional properties. In adult rat cardiac tissue, angiotensin II (AngII) via AT1 receptor binding and AngII-regulated expression of transforming growth factor beta-1 (TGF-β1) each upregulate collagen transcription. AT1 and AT2 receptor subtypes are developmentally regulated; both have been localized in fetal tissue where the AT2 receptor is considered a determinant of morphogenesis. We sought to determine whether blockade of either receptor would result in attenuation of collagen mRNA expression and fibrillar collagen accumulation and alter TGF-β1 mRNA expression in the developing fetal heart examined at birth. Methods: Pregnant rats were treated either with an AT1 receptor antagonist losartan or an AT2 receptor antagonist PD123319 and compared with untreated age-matched controls. Offspring were studied within 24 h of birth. Type I and type III collagen mRNA expression, as well as TGF-β1 mRNA expression, were examined by in situ hybridization. Collagen concentration was determined spectrophotometrically by picrosirius red staining and type I and III collagens were detected by immunoblotting. Results: We found: (1) comparable birth weights in control and PD123319- treated animals, but reduced body weight in newborn losartan-treated animals; (2) compared to untreated animals, type I collagen and TGF-β1 mRNA expression in cardiac tissue were each equally reduced in both losartan and PD123319-treated animals; (3) increased type III collagen mRNA expression in both PD123319- and losartan-treated groups; and (4) a significant decrease in total soluble cardiac collagen concentration in both losartan and PD123319- treated groups, confirmed by attenuated immunoreactivity of type I and III collagens in whole heart extracts by Western blotting. Conclusions: The results of these pharmacologic interventions suggest AngII receptors are expressed in cardiac tissue during gestation, where both AT1 and AT2 receptors are involved in the regulation of type I and III collagen expression and structural protein accumulation. These effects appear to be mediated, in part, by attenuated cardiac TGFβ1 levels. The marked decrease in newborn cardiac collagen content has yet undefined functional consequences.

UR - http://www.scopus.com/inward/record.url?scp=0033002505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033002505&partnerID=8YFLogxK

U2 - 10.1016/S0008-6363(99)00111-X

DO - 10.1016/S0008-6363(99)00111-X

M3 - Article

VL - 43

SP - 165

EP - 172

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -